{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:05:29Z","timestamp":1769601929646,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Education, Science and Technology, Republic of Korea","award":["2010K001288"],"award-info":[{"award-number":["2010K001288"]}]},{"name":"Ministry of Education, Science and Technology, Republic of Korea","award":["HI2C1440"],"award-info":[{"award-number":["HI2C1440"]}]},{"name":"Ministry of Health & Welfare, Republic of Korea"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.lungcan.2016.02.013","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T18:35:56Z","timestamp":1456684556000},"page":"57-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models"],"prefix":"10.1016","volume":"95","author":[{"given":"Han Na","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Ran","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Won","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Moo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung-Ho","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Ji","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Yeun","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun A","family":"Youn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Hwan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2016.02.013_bib0005","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1097-2765(03)00350-2","article-title":"An open-and-shut case? Recent insights into the activation of EGF\/ErbB receptors","volume":"12","author":"Burgess","year":"2003","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.lungcan.2016.02.013_bib0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"5676","key":"10.1016\/j.lungcan.2016.02.013_bib0015","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"36","key":"10.1016\/j.lungcan.2016.02.013_bib0020","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"Suppl. 18","key":"10.1016\/j.lungcan.2016.02.013_bib0025","first-page":"1S","article-title":"Targeting the epidermal growth factor receptor for cancer therapy","volume":"20","author":"Mendelsohn","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2016.02.013_bib0030","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.lungcan.2016.02.013_bib0035","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9674","key":"10.1016\/j.lungcan.2016.02.013_bib0040","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lungcan.2016.02.013_bib0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4161\/cbt.10.7.12793","article-title":"Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR","volume":"10","author":"Basavaraj","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"8","key":"10.1016\/j.lungcan.2016.02.013_bib0050","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","article-title":"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial","volume":"14","author":"Vermorken","year":"2013","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2016.02.013_bib0055","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.lungcan.2012.11.017","article-title":"A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)","volume":"79","author":"Kim","year":"2013","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2016.02.013_bib0060","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2016.02.013_bib0065","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.ejca.2008.12.012","article-title":"Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway","volume":"45","author":"Meira","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2016.02.013_bib0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4110\/in.2012.12.4.155","article-title":"Affinity maturation of an epidermal grwoth factor receptor targeting human monoclonal antibody ER414 by CDR mutation","volume":"12","author":"Chang","year":"2012","journal-title":"Immune Network"},{"issue":"1","key":"10.1016\/j.lungcan.2016.02.013_bib0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jbiotec.2009.09.023","article-title":"A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab","volume":"145","author":"Hong","year":"2010","journal-title":"J. Biotechnol."},{"issue":"10","key":"10.1016\/j.lungcan.2016.02.013_bib0080","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1158\/1535-7163.MCT-12-0311","article-title":"Activation of IL-6R\/JAK1\/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation","volume":"11","author":"Kim","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.lungcan.2016.02.013_bib0085","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/ijc.26427","article-title":"A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment","volume":"131","author":"Zhang","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2016.02.013_bib0090","first-page":"49","article-title":"Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor","volume":"9","author":"Lin","year":"1998","journal-title":"Cell Growth Differ."},{"issue":"5","key":"10.1016\/j.lungcan.2016.02.013_bib0095","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2016.02.013_bib0100","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1078-0432.CCR-06-1542","article-title":"A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing","volume":"13","author":"Fracasso","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2016.02.013_bib0105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1158\/0008-5472.226.65.1","article-title":"Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer","volume":"65","author":"Amann","year":"2005","journal-title":"Cancer Res."},{"issue":"Pt. 1","key":"10.1016\/j.lungcan.2016.02.013_bib0110","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1078-0432.795.11.2","article-title":"The effects of cetuximab alone and in combination with radiation and\/or chemotherapy in lung cancer","volume":"11","author":"Raben","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2016.02.013_bib0115","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1124\/mol.107.034827","article-title":"Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1\/S phase arrest in human non-small-cell lung cancer cell lines","volume":"72","author":"Ling","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.lungcan.2016.02.013_bib0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1476-4598-6-63","article-title":"Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha","volume":"6","author":"Lu","year":"2007","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2016.02.013_bib0125","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2165\/00003495-200868120-00001","article-title":"Promising newer molecular-targeted therapies in head and neck cancer","volume":"68","author":"Wang","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2016.02.013_bib0130","article-title":"GC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands","author":"Lim","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.lungcan.2016.02.013_bib0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.lungcan.2016.02.013_bib0140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol. Cancer Res."},{"issue":"16","key":"10.1016\/j.lungcan.2016.02.013_bib0145","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-09-0888","article-title":"Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials","volume":"15","author":"Jackman","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2016.02.013_bib0150","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(11)70189-9","article-title":"Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study","volume":"12","author":"O'Byrne","year":"2011","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2016.02.013_bib0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.critrevonc.2006.02.006","article-title":"Cetuximab in advanced non-small cell lung cancer","volume":"59","author":"Rossi","year":"2006","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.lungcan.2016.02.013_bib0160","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2004.06.002","article-title":"Epidermal growth factor receptor in tumor angiogenesis","volume":"18","author":"Ellis","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.lungcan.2016.02.013_bib0165","first-page":"1459","article-title":"Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2016.02.013_bib0170","first-page":"3739","article-title":"Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells","volume":"6","author":"Ciardiello","year":"2000","journal-title":"Clin. Cancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216302343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216302343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T15:45:41Z","timestamp":1656258341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216302343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":34,"alternative-id":["S0169500216302343"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.02.013","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}